Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus + vandetanib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of sirolimus and vandetanib has been studied primarily for the treatment of recurrent glioblastoma. Sirolimus (also known as rapamycin) is an FDA-approved drug that inhibits mammalian target of rapamycin (mTOR), a member of the phosphoinositide 3-Kinase signaling pathway. Vandetanib is a drug that inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2). The combination of these two drugs targets specific molecular alterations in glioblastoma with the aim of more effectively killing tumor cells and potentially increasing survival.
- Other names
- rapamycin + vandetanib
02
Targets
mTOR (Mammalian target of rapamycin kinase)VEGFR4 (Vascular endothelial growth factor Receptor-3)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on sirolimus + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus + vandetanib.